In an experimental plan primarily designed to identify anti-Aβ and anti-tau activities of YZT in vitro AD models, 7PA2 and SH-SY5Y-P301L cells, we found that YZT did not regulate the protein levels of full length APP (Fl-APP) and CTFs. The gene discussed is MAPT; the disease is Alzheimer disease.